BRTX Insider Trading

Insider Ownership Percentage: 21.60%
Insider Buying (Last 12 Months): $15,707.32
Insider Selling (Last 12 Months): $0.00

BioRestorative Therapies Insider Trading History Chart

This chart shows the insider buying and selling history at BioRestorative Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioRestorative Therapies Share Price & Price History

Current Price: $1.38
Price Change: Price Decrease of -0.01 (-0.72%)
As of 03/28/2024 01:00 AM ET

This chart shows the closing price history over time for BRTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

BioRestorative Therapies Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2023Dale BroadrickMajor ShareholderBuy1,000$2.80$2,800.00306,073View SEC Filing Icon  
7/25/2023Lance AlstodtCEOBuy4,200$2.44$10,248.00184,418View SEC Filing Icon  
3/31/2023Francisco SilvaVPBuy747$3.56$2,659.32159,690View SEC Filing Icon  
2/22/2023Dale BroadrickMajor ShareholderBuy6,000$2.86$17,160.00305,073View SEC Filing Icon  
2/1/2023Lance AlstodtCEOBuy400$3.10$1,240.00187,321View SEC Filing Icon  
1/27/2023Lance AlstodtCEOBuy200$3.01$602.00186,921View SEC Filing Icon  
1/20/2023Lance AlstodtCEOBuy200$3.13$626.00186,721View SEC Filing Icon  
1/18/2023Lance AlstodtCEOBuy400$3.11$1,244.00186,521View SEC Filing Icon  
1/9/2023Lance AlstodtCEOBuy100$3.08$308.00186,121View SEC Filing Icon  
12/23/2022Lance AlstodtCEOBuy300$3.01$903.00186,021View SEC Filing Icon  
12/7/2022Lance AlstodtCEOBuy1,800$2.99$5,382.00185,721View SEC Filing Icon  
11/21/2022Francisco SilvaVPBuy943$2.62$2,470.66166,046View SEC Filing Icon  
11/18/2022Lance AlstodtCEOBuy1,000$2.88$2,880.00183,921View SEC Filing Icon  
10/11/2022Francisco SilvaVPBuy806$3.69$2,974.14164,378View SEC Filing Icon  
9/23/2022Dale BroadrickMajor ShareholderBuy300$2.83$849.00298,873View SEC Filing Icon  
9/22/2022Lance AlstodtCEOBuy200$2.92$584.00182,921View SEC Filing Icon  
8/29/2022Francisco SilvaVPBuy2,816$3.21$9,039.36163,572View SEC Filing Icon  
8/26/2022Francisco SilvaVPBuy2,600$3.35$8,710.00160,756View SEC Filing Icon  
7/12/2022Dale BroadrickMajor ShareholderBuy900$2.97$2,673.00298,373View SEC Filing Icon  
7/12/2022Lance AlstodtCEOBuy700$2.95$2,065.00182,721View SEC Filing Icon  
7/6/2022Dale BroadrickMajor ShareholderBuy100$3.38$338.00297,473View SEC Filing Icon  
6/30/2022Dale BroadrickMajor ShareholderBuy1,900$3.08$5,852.00297,373View SEC Filing Icon  
6/30/2022Lance AlstodtCEOBuy1,100$3.10$3,410.00182,021View SEC Filing Icon  
6/21/2022Dale BroadrickMajor ShareholderBuy100$3.68$368.00295,473View SEC Filing Icon  
6/17/2022Dale BroadrickMajor ShareholderBuy600$3.80$2,280.00295,373View SEC Filing Icon  
6/15/2022Dale BroadrickMajor ShareholderBuy1,200$3.72$4,464.00292,773View SEC Filing Icon  
6/15/2022Lance AlstodtCEOBuy700$3.68$2,576.00180,321View SEC Filing Icon  
6/15/2022Robert Eugene KristalCFOBuy194$3.61$700.347,994View SEC Filing Icon  
6/13/2022Dale BroadrickMajor ShareholderBuy1,300$3.92$5,096.00291,573View SEC Filing Icon  
6/13/2022Lance AlstodtCEOBuy200$3.95$790.00179,121View SEC Filing Icon  
6/10/2022Dale BroadrickMajor ShareholderBuy600$4.23$2,538.00290,273View SEC Filing Icon  
6/8/2022Dale BroadrickMajor ShareholderBuy2,400$4.33$10,392.00288,673View SEC Filing Icon  
6/8/2022Lance AlstodtCEOBuy100$4.28$428.00178,921View SEC Filing Icon  
6/7/2022Robert Eugene KristalCFOBuy200$4.56$912.007,800View SEC Filing Icon  
6/6/2022Dale BroadrickMajor ShareholderBuy3,000$4.93$14,790.00282,673View SEC Filing Icon  
6/2/2022Dale BroadrickMajor ShareholderBuy1,000$4.69$4,690.00278,473View SEC Filing Icon  
6/1/2022Lance AlstodtCEOBuy200$4.60$920.00178,821View SEC Filing Icon  
5/26/2022Dale BroadrickMajor ShareholderBuy4,950$3.51$17,374.50259,303View SEC Filing Icon  
5/26/2022Lance AlstodtCEOBuy2,700$3.52$9,504.00178,621View SEC Filing Icon  
5/2/2022Lance AlstodtCEOBuy400$3.95$1,580.00175,921View SEC Filing Icon  
4/8/2022Robert Eugene KristalCFOBuy7,600$5.71$43,396.007,600View SEC Filing Icon  
4/5/2022Dale BroadrickMajor ShareholderBuy46,000$5.71$262,660.00254,353View SEC Filing Icon  
3/31/2022Dale BroadrickMajor ShareholderBuy10,700$4.72$50,504.00View SEC Filing Icon  
3/29/2022Dale BroadrickMajor ShareholderBuy5,000$5.12$25,600.00View SEC Filing Icon  
3/21/2022Dale BroadrickMajor ShareholderBuy10,000$4.35$43,500.00View SEC Filing Icon  
3/9/2022Dale BroadrickMajor ShareholderBuy11,875$4.00$47,500.00View SEC Filing Icon  
3/7/2022Dale BroadrickMajor ShareholderBuy24,392$4.43$108,056.56View SEC Filing Icon  
3/3/2022Dale BroadrickMajor ShareholderBuy47,648$5.47$260,634.56View SEC Filing Icon  
3/1/2022Dale BroadrickMajor ShareholderBuy2,270$5.55$12,598.50View SEC Filing Icon  
1/24/2022Lance AlstodtCEOBuy1,470$3.40$4,998.00View SEC Filing Icon  
1/5/2022Lance AlstodtCEOBuy2,000$3.85$7,700.00View SEC Filing Icon  
12/1/2021Lance AlstodtCEOBuy799$5.50$4,394.50View SEC Filing Icon  
11/22/2021Lance AlstodtCEOBuy396$6.31$2,498.76View SEC Filing Icon  
11/19/2021Francisco SilvaVPBuy4,000$6.66$26,640.00View SEC Filing Icon  
11/16/2021Lance AlstodtCEOBuy4,500$6.71$30,195.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for BioRestorative Therapies (OTCMKTS:BRTX)

6.93% of BioRestorative Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BRTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

BioRestorative Therapies Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2023Wells Fargo & Company MN11,562$51K0.0%+52,454.5%0.248%Search for SEC Filing on Google Icon
8/11/2023Geode Capital Management LLC43,776$0.19M0.0%+219.6%0.937%Search for SEC Filing on Google Icon
5/16/2023State Street Corp20,459$70K0.0%N/A0.543%Search for SEC Filing on Google Icon
5/15/2023Two Sigma Advisers LP29,100$99K0.0%N/A0.772%Search for SEC Filing on Google Icon
5/15/2023Two Sigma Investments LP17,026$58K0.0%N/A0.452%Search for SEC Filing on Google Icon
2/15/2023Boothbay Fund Management LLC12,296$34K0.0%-61.6%0.334%Search for SEC Filing on Google Icon
2/8/2023Cambridge Investment Research Advisors Inc.28,050$77K0.0%+22.0%0.768%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.135,046$0.71M0.0%-11.4%3.720%Search for SEC Filing on Google Icon
5/12/2022Ayrton Capital LLC77,762$0.41M0.5%-31.0%2.144%Search for SEC Filing on Google Icon
5/12/2022Cambridge Investment Research Advisors Inc.23,001$0.12M0.0%N/A0.634%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
BioRestorative Therapies logo
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Read More on BioRestorative Therapies

Today's Range

Now: $1.38
Low: $1.36
High: $1.42

50 Day Range

MA: $1.51
Low: $1.28
High: $3.45

52 Week Range

Now: $1.38
Low: $1.20
High: $7.13

Volume

33,956 shs

Average Volume

484,160 shs

Market Capitalization

$6.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

61.85

Who are the company insiders with the largest holdings of BioRestorative Therapies?

BioRestorative Therapies' top insider investors include:
  1. Dale Broadrick (Major Shareholder)
  2. Lance Alstodt (CEO)
  3. Francisco Silva (VP)
  4. Robert Eugene Kristal (CFO)
Learn More about top insider investors at BioRestorative Therapies.